Part:BBa_K4170043
crRNA targeting the miR-17-5P (mismatch design) under T7 promoter
This plasmid contains all the basic genetic parts required for the in vitro transcription of the crRNA-5pm regulated by T7 promoter. crRNA-5pm consists of the loop sequence for the construction of Cas13a/crRNA duplex and a spacer sequence with a mismatch (C→G) in position 14 generating no perfect hybridization of the spacer with the mature miRNA-17-5p. This genetic device is a part of the meta-CRISPR part collection developed by iGEM22_Thessaloniki_Meta.
Meta-CRISPR part collection
The meta-CRISPR part collection was developed in accordance with standardization, modularity and standard assembly rules aiming to enhance the CRISPR/crRNA applicability in synthetic biology projects. This collection allows the interchangeability of the genetic parts and the automation of construction following a standardized Golden Gate-based cloning strategy. Utilizing the meta-CRISPR collection, future iGEM teams can select the desired combination of DNA parts depending on the specific application of the CRISPR method (https://2022.igem.wiki/thessaloniki-meta/part-collection). Through the combination of different promoters and LbuCas13a coding sequences, one can select the desired LbuCas13a expression system, for example under the transcriptional control of the T7 or the pRha promoter. In addition, by combining the suitable genetic parts, researchers can select the purification method of the recombinant LbuCas13a protein either from inclusion bodies or from the soluble cytoplasmic fraction of the bacteria. Regarding the crRNA, utilizing the guidelines provided on the crPrep-crRNA preparation kit one can easily in silico design and produce the necessary crRNA sequence depending on the target miRNA utilizing the standardized cloning method and requiring only one additional primer. Last but not least, the LbuCas13a coding device can be assembled with the crRNA transcription system in a single plasmid enabling the simultaneous production of the LbuCas13a/crRNA complex in bacteria.
Usage and Biology
miR-17 and cancer
MiR-17 is an oncogene that appertains to the MiR-17-92 cluster. This cluster is located in chromosome 13 and encodes for six individual miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92a) (Concepcion et al., 2013). The miRNAs of this cluster are essential modulators of constitutive cellular processes like differentiation, metastases, apoptosis, proliferation. The carcinogenic role of miR-17-92 cluster in different cancers has been confirmed, while it seems to interact with the transcription factors E2Fs and c-Myc, which play a crucial role in cell-cycle regulation during tumorigenesis. As reported, miR-17 is significantly expressed in many types of cancer, including breast cancer, gastric cancer, prostate cancer, and NSCLC, and thus can be an efficient non-invasive biomarker for the screening of cancer patients.Recent literature has shown that in NSCLC, the mature strand mir-17-5p is associated mainly with LKB1/AMPK pathway and PTEN/PI3K/Akt pathway.
LKB1/AMPK pathway.
The Liver Kinase B1 (LKB1, also known as STK11) is an oncosuppressor gene, encoding a serine threonine kinase. LKB1 mutations are frequently associated with NSCLC. LKB1 positively regulates the AMP-activated protein kinase (AMPK) and at least 12 additional AMPK-related downstream kinases, involved in the control of cell growth , metabolism and in the regulation of cellular response to energy stress and establishment of cell polarity (Ciccarese et al., 2019). Deregulation of LKB1 signaling has been implicated in oncogenesis across many cancer types. Considering the scientific updates, overexpression of mir-17-5p seems to repress the levels of LKB1. Low levels of LKB1 influence the AMPK pathway and thus contribute to the deregulation of cell growth control (Borzi et al., 2021).
PTEN/PI3K/Akt pathway
Phosphatase and tensin homologue deleted on chromosome 10(PTEN) is a dual lipid and protein phosphatase. PTEN negatively regulates PI3K, leading to activation of the PI3K/Akt pathway. AKT activation stimulates cell cycle progression, survival, metabolism and migration through phosphorylation of many physiological substrates. Furthermore, PTEN influences the nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) protein levels, which is a key transcription factor for osteoclastogenesis (Carnero et al., 2008). Osteoclastogenesis is connected with bone metastasis in NSCLC. mir-17-5p appears to promote osteoclastogenesis, by interplaying with PTEN and activating the PI3K/Akt pathway (Wang et al., 2021).
Design considerations
This plasmid was constructed with direct PCR amplification of PSB1C3 plasmid utilizing 2 pairs of primers. The first pair consists of a primer (loop RVS standard) binding to the Biobrick prefix sequence containing an overhang with the stem-loop sequence of the crRNA and the T7 promoter sequence and a primer (loop FWD standard) binding to the backbone of the plasmid. The second pair of primers consists of a primer (5pm spacer FWD interchangeable) binding to the Biobrick suffix sequence containing an overhang with the spacer sequence of the crRNA and a primer (spacer RVS standard) binding to the backbone of the plasmid.
Basic parts assembled for device construction
The part sample which is flanked at the beginning and the end with prefix and suffix respectively, is composed of the following basic parts assembled together in series and downstream of the prefix:
- Bacterial terminator (for LacI CDS) (located at backbone): putative bacterial transcription terminator
- Biobrick Prefix sequence: BioBrick prefix for parts that do not start with "ATG"
- T7 promoter: promoter for bacteriophage T7 RNA polymerase T7 gene 10 (Olins and Rangwala, 1989)
- crRNA-5pm CDS (https://parts.igem.org/Part:BBa_K4170043): coding sequence of crRNA which targets miRNA-17-5p containing a restriction site of SapI enzyme for the linearization of the plasmid
- Biobrick Suffix sequence : universal suffix for all parts
- His operon terminator (downstream of Suffix) (located at backbone): putative transcription terminator from the E. coli
Cloning procedure
The plasmid with the crRNA targeting the miR-17-5P (mismatch design-BBA_4170028) under the T7 promoter for the in vitro transrciption was constructed with direct PCR amplification of PSB1C3 plasmid utilizing 2 pairs of primers followed by a Golden Gate-based ‘SevaBrick Assembly’ method. The first pair consists of a primer (loop RVS standard) binding to the Biobrick prefix sequence containing an overhang with the stem-loop sequence of the crRNA and a primer (loop FWD standard) binding to the backbone of the plasmid. The second pair of primers consists of a primer (5pm spacer FWD interchangeable) binding to the Biobrick suffix sequence containing an overhang with the spacer sequence of the crRNA, and a primer (spacer RVS standard) binding to the backbone of the plasmid. This strategy enables the handy and fast alternation of the overhang sequence of the interchangeable primer for the construction of any crRNA flanked in PSB1C3 plasmid keeping the other primers as customary components. The plasmid contains all the basic genetic parts required for the in vitro transcription of the crRNA-5pm regulated by T7 promoter.
Step 1
- PCR amplification with loop RVS standard and loop FWD standard primers using the PSB1C3 plasmid as a template. These primers produce the loop sequence of the crRNA incorporated with the CmR sequence (confers resistance to chloramphenicol) of the PSB1C3 plasmid. 'This PCR produces the loop part ready for Golden Gate assembly. The loop part is ready to use for any crRNA constructed with this method as the stem-loop sequence is universal for all crRNAs.
- PCR amplification with 5pm spacer FWD interchangeable and spacer RVS standard primers using the PSB1C3 plasmid as a template. This PCR produces the 5pm-spacer part ready for Golden Gate assembly.
According to the results of the agarose gel electrophoresis, all PCR amplification were succesful.
Step 2
Golden Gate assembly of the PCR amplified loop part and 5pm-spacer part for the efficient construction of the crRNA-5pm coding sequence under the transcriptional control of the T7 promoter. The Golden Gate assembly products underwent transformation into E.coli DH5a competent cells and then colony PCR was performed, using the primers VR and VF2. Picking sample from different colonies and then evaluating the results on a 1 % agarose gel electrophoresis we concluded that the Golden Gate assembly was successful. As depicted on the following figure from all colonies the desired inserts were successfully amplified. For the colony PCR procedure, from the agar plate half amount of each colony was picked and diluted on 10 μl of dH20. The other half amount was picked for liquid overnight culture
In vitro transcription of the crRNA-17-5P (mismatch design) under the control of T7 promoter
The first step for the in vitro transcription of the crRNA-17-3P is the plasmid linearization through digestion with the restriction enzyme SapI. The SapI recognition site is located downstream of the crRNA sequence.
The linearized DNA template bands were purified by Nuclospin Gel and PCR Clean-up kit (Macherey-Nagel, Duren, Germany) and a second purification step with phenol/chloroform was performed.
The next step was the template-directed synthesis of the crRNA through in vitro transcription using T7 Polymerase (HiScribe T7 High Yield RNA Synthesis Kit, NEB) and the purification of the products, using Monarch RNA Cleanup Kit (NEB). In the following figure the crRNA transcripts are depicted on a 3% agarose gel electrophoresis after in vitro transcription. Additional non-selective RNA products are depicted at higher molecular weight.
The crRNA transcripts are further purified from other non-selective RNA products through a second clean-up procedure with the PCR Clean-up kit (Macherey-Nagel, Duren, Germany). The results of the additional clean up step are depicted on the following figure.
General methodology for the in silico design and experimental production of any desired crRNA.
Seeking to simplify the in silico design and experimental process for the production of a functional miRNA-targeted crRNA, we introduce a methodology for the crRNA preparation. Detailed information regarding this methodology is provided on the crPrep crRNA preparation kit section on the contribution page of iGEM Thessaloniki_Meta. The provided guidelines cover the entire crRNA developmental process from in silico design to in vitro transcription and allow future iGEM teams to efficiently easily produce the desired crRNA even if they do not have significant expertise in designing genetic sequences for cloning applications. Further information are also provided on the registry page of the part BBa_K4170019 (https://parts.igem.org/Part:BBa_K4170019).
Sequence- crRNA 17-5p-mismatch design and in silico evaluation
The sequence is consisted of 2 main parts. The first part is called Repeat Part and it is a standard nucleotide sequence that binds to the Recognition Lobe of LbuCas13a and forms a stable complex with it. The second part is called spacer or detection part and it is responsible for the detection of the miR 17-5p. The Repeat part contains 31 nucleotides, and the spacer sequence is designed to contains 20 nucleotides that are complementary to the target miR sequence(Liu et al., 2017). After the selection of the 20 nucleotides of the spacer sequence, we introduced an artificial mismatch at the position 16. The nucleotide that replaced the corresponding one at the spacer sequence is its complementary. Based on the literature the artificial mismatch leads to a decrease at the fluorescence signal from the trans cleavage activity of the protein, when the crRNA interacts with a different RNA sequence compared to the target RNA(Shan et al., 2019).
The first step of the in-silico evaluation is the evaluation of its thermodynamic properties. The software used for this task is ViennaRNA(Lorenz et al., 2011. The properties studied were : Minimum Free Energy, GC content of the sequence, Linearity of Detection Part, the Binding energy with the target miRNA and perfect matches.
The Minimum Free Energy is a measure of stability of the RNA and the negative it is the more stable will be. The Vienna Software is calculating the energy based on the secondary optimal structure. The value of -10.2 kcal/mol and a probability of the Minimum Free Energy in the ensemble is 0.64 or 64% suggesting a stable secondary structure that is adopted from the majority of the crRNA molecules. GC content is ratio of the Guanine and Cytokine that are present in the sequence. The higher the ratio, the more stable the sequence will be. This phenomenon is based on the different chemical groups that are present in every nucleotide resulting stronger hydrogen bonds in comparison with other nucleotides and the value 0.48 is low in terms of stability since a ratio > 0.5 is preferable. Linearity Of Detection Part (LODP) shows the secondary structure of the detection part of the crRNA sequence. Closer to 0 more linear will this part be. The linear structure of the detection part of crRNA is highly associated with the proper function of the LbuCas13a protein. The value of -4.1 kcal/mol is the result of unwanted hydrogen bonds in the spacer sequence and based on this energy value may lead to system’s dysfunctionality. Binding energy is the energy term of the difference between the Gibbs free energy of the complex RNA and the free energy of crRNA and miRNA target. The binding energy is calculated using the secondary structure of the sequences. Since the value -36.7 kcal/mol of the binding energy is nearly 4 times the MEF of the crRNA sequence then the stability of complex is the preferable energetical state and the binding is predicted to be immediate. Perfect Matches is a measure of evaluation of the RNA complex that is formed by crRNA and miRNA target sequences. The secondary structure of the complex is calculated through RNAduplex, and perfect matches is the ratio of the nucleotides that are bind properly in detection part of the crRNA sequences. The ratio of 0.95 (19/20) is showing that the binding on the spacer sequence will be exactly as the suggested binding upon designing the sequence. The spacer sequence designed to pair with the miRNA with 19 bonds since it has an artificial mismatch. The secondary structure of the miRNA after binding with the sequence that predicted from RNAduplex is:)))).))))))))))))))) that ) shows a pair nucleotide and . shows an unpaired one. The predicted secondary structure of the crRNA sequence and the complex formed between the crRNA and miRNA sequence are demonstrated on the next figure:
The next step for the in-silico evaluation is the molecular docking with the LbuCas13a protein. For this process, the utilized pdf file for LbuCas13a acquired from Protein Data Bank (ID 5XWY) and the pdf file for the crRNA 17-5p-mismatch sequence generated through the RNAComposer Sever. The docking algorithm was the HDOCK docking algorithm for the webserver(Zhang Di Yumeng Yan, 2017). The docking model selected was the best model that had the more negative value based on the scoring algorithm of HDOCK server(Wang et al., 2020).
The docking score is the energy score calculated through the scoring function of HDOCK algorithm.[4] The docking score is negatively related to the stability of the complex, meaning the more negative is the docking score more stable the complex receptor-ligand will be. The value of -349.98 kcal/mol shows that the complex formation is the energetical favorable state. The Ligand Root Mean Square Deviation is showing the difference between the positions of nucleotides of the ligand’s structure before and after docking. The ligand RMSD value of 49.91 Angstrom shows a major change in the conformation of the ligand which is acceptable since the ligand in this specific docking process is an RNA sequence of 51 nucleotides. The interaction site of the LbuCas13a based on the best model from HDOCK docking algorithm is the NUC Lobe and the interaction site of the crRNA sequence is the Repeat part of the crRNA 17-3p-mismatch. In comparison with the literature (Liu et al., 2017), the protein-RNA interactions are on the REC Lobe of the protein and the Repeat Part of the crRNA sequence suggesting that the docking model resulted to a different conformation of the 2 molecules.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 71
Citations
1. Borzi, C., Ganzinelli, M., Caiola, E., Colombo, M., Centonze, G., Boeri, M., Signorelli, D., Caleca, L., Rulli, E., Busico, A., Capone, I., Pastorino, U., Marabese, M., Milione, M., Broggini, M., Garassino, M., Sozzi, G. and Moro, M., 2021. LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress–Based Treatments. Journal of Thoracic Oncology, 16(8), pp.1298-1311.
2. Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W. and Leal, J., 2008. The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications. Current Cancer Drug Targets, 8(3), pp.187-198.
3. Ciccarese, F., Zulato, E. and Indraccolo, S., 2019. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective. Oxidative Medicine and Cellular Longevity, 2019, pp.1-16.
4. Concepcion, C., Bonetti, C. and Ventura, A., 2012. The MicroRNA-17-92 Family of MicroRNA Clusters in Development and Disease. The Cancer Journal, 18(3), pp.262-267.
5.Liu, L. et al. (2017) ‘The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a’, Cell, 170(4), pp. 714-726.e10. Available at: https://doi.org/10.1016/j.cell.2017.06.050.
6.Lorenz, R. et al. (2011) ‘ViennaRNA Package 2.0’, Algorithms for Molecular Biology, 6(1), pp. 1–14. Available at: https://doi.org/10.1186/1748-7188-6-26.
7.Shan, Y. et al. (2019) ‘High-Fidelity and Rapid Quantification of miRNA Combining crRNA Programmability and CRISPR/Cas13a trans-Cleavage Activity’, Analytical Chemistry, 91(8), pp. 5278–5285. Available at: https://doi.org/10.1021/acs.analchem.9b00073.
8.Wang, L. et al. (2020) ‘Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein’, Theranostics, 11(2), pp. 649–664. Available at: https://doi.org/10.7150/thno.51479. Zhang Di Yumeng Yan (2017) ‘HDOCK : a web server for protein-protein and protein -DNA/RNA docking based on a hybrid strategy’.
| None |